Drug intelligence / Profile preview

Fostera Gold PCV MH

Development stage: Unknown
Lead developer: Zoetis
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Fostera Gold PCV MH** is a bivalent, chimeric vaccine used in swine for the prevention of diseases caused by porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhp). It contains two genotypes of PCV2 (2a and 2b) and includes antigens from M. hyopneumoniae, providing the broadest range of protection among commercial PCV2 vaccines. The vaccine elicits both humoral (antibody-mediated) and cell-mediated immune responses, important for protection against PCV2 and Mhp. Its efficacy includes protection against the prevalent PCV2d strain, due to demonstrated cross-protection between genotypes[1][3][5].

Brand names: Fostera Gold PCV MH
Other names: FOS-G

Beyond the preview

Go deeper on Fostera Gold PCV MH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fostera Gold PCV MH.

Explore the full profile